Stopping memantine requires a gradual taper overseen by a prescriber, not an abrupt halt. Case reports have linked sudden cessation to behavioral disturbances that were difficult to reverse, and clinical guidelines consistently recommend stepping the dose down slowly while monitoring for any cognitive or mood changes. Because memantine lingers in the body far longer than most medications, the tapering process and the watch period afterward both deserve more attention than many patients and families expect.
Why You Should Not Stop Memantine Suddenly
Memantine works by dampening overactive signaling at certain receptors in the brain. When the drug is removed all at once, those receptors can become flooded with stimulation they had been shielded from, and the result can be a rebound in symptoms that is worse than the patient’s baseline before treatment. A report in Geriatrics & Gerontology International described two patients who developed significant behavioral disturbance after abrupt cessation of memantine. Restarting the drug improved their symptoms, but additional medications were needed on top of memantine to get them back to where they had been, meaning the damage from stopping cold turkey was not fully or easily undone.1PubMed. Two cases of discontinuation syndrome following cessation of memantine
This kind of discontinuation syndrome is not unique to memantine; many drugs that act on the central nervous system carry similar risks. But the long half-life of memantine, which sits somewhere around 60 to 80 hours in humans, gives a deceptive sense of security.2PubMed Central. Pharmacokinetics of memantine in rats and mice The drug clears slowly enough that a person might feel fine for days after their last dose, leading them to believe they tolerated the stop well. Problems can surface a week or more later, once blood levels have finally dropped below the therapeutic range. That delay makes it easy to blame the decline on something else entirely.
When Stopping Memantine Makes Sense
Deciding to discontinue is a clinical judgment, not something to do because the prescription feels unnecessary or because a refill was missed. Evidence-based deprescribing guidelines identify several situations where a trial of stopping memantine is reasonable:
- No clear benefit: The person never showed a meaningful response to the medication, or the benefit seems to have faded over time.
- Wrong indication: The drug was started for a condition it was not designed to treat, such as mild cognitive impairment rather than moderate-to-severe dementia.
- Severe or end-stage dementia: When the disease has progressed to a point where the drug’s modest effects on cognition are no longer clinically relevant, deprescribing can reduce pill burden and side-effect exposure.
- Intolerable side effects: Dizziness, confusion, or constipation that the patient finds distressing and that does not resolve with dose adjustment.
These criteria come from an international guideline development process published in the Medical Journal of Australia, which aimed to help clinicians identify individuals suitable for a deprescribing trial and to standardize how treatment is tapered and monitored.3PubMed. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Canadian consensus recommendations echo the same principles, adding that patient and caregiver preferences should be woven into every discontinuation decision and that the drug should be restarted if cognition or function worsens noticeably after tapering.4PubMed Central. CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia
One important caution: if the person’s neuropsychiatric symptoms, such as agitation, aggression, or delusions, improved after memantine was started, guidelines recommend continuing the drug. Clinicians should not attempt deprescribing while those symptoms are still active or unstable.4PubMed Central. CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia
A Practical Tapering Approach
There is no single universally mandated taper schedule for memantine, partly because formal trials specifically examining memantine-only withdrawal are essentially nonexistent. A Cochrane systematic review on discontinuing dementia medications found trials on cholinesterase inhibitor withdrawal but stated plainly that no trials assessed withdrawal of memantine only, leaving clinicians without high-quality evidence to guide the process.5PubMed Central. Withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia In practice, most prescribers follow a conservative, stepwise plan based on the drug’s own titration schedule in reverse.
Memantine is typically started at 5 mg once daily and increased by 5 mg increments each week until the target dose of 20 mg per day is reached. A common tapering strategy simply reverses that ladder: drop from 20 mg to 15 mg for a week, then to 10 mg for a week, then to 5 mg for a week, then stop. Some clinicians prefer to hold each step for two weeks rather than one, given the long half-life. The goal is to give the brain time to readjust to each lower level of receptor blockade before reducing further.
If the person is taking an extended-release capsule formulation (28 mg once daily is the most common extended-release dose), the prescriber may switch to the immediate-release tablets during the taper because those are easier to split into smaller increments. A dry syrup formulation of memantine has also been developed specifically to improve dosing flexibility and reduce caregiver burden, and it has been shown to be bioequivalent to the standard tablet.6PubMed Central. Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies A liquid or syrup can make fine-grained dose reductions easier, especially for patients who have trouble swallowing or when a prescriber wants to use steps smaller than 5 mg.
What to Watch for During and After the Taper
The most common symptoms caregivers and clinicians report after memantine is reduced or stopped fall into two clusters: cognitive decline and mood changes. A study of nursing home residents with Alzheimer’s disease found that those who discontinued memantine for nonmedical reasons, such as formulary restrictions or family decisions, showed significant worsening compared to those who stayed on the drug. The symptoms that deteriorated most prominently grouped into cognition and mood.7Journal of the American Medical Directors Association. Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer’s Disease
In practical terms, that means caregivers and family members should be watching for increased confusion, disorientation, or difficulty with tasks the person had been managing. Mood-related changes to look for include new irritability, agitation, withdrawal, or depressive symptoms. These problems may not appear immediately because of memantine’s slow clearance; the most informative monitoring window extends at least four to six weeks after the final dose.
If any of these changes appear during the taper, the usual recommendation is to go back up to the last dose that was tolerated and hold there. If they appear after the drug has been fully stopped, guidelines suggest restarting memantine and stabilizing the person before deciding whether to try again later or to resume treatment indefinitely.4PubMed Central. CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia A decline that looks subtle on paper, a point or two on a screening test, may translate into real distress for the person and for those caring for them, so erring on the side of restarting rather than pushing through is the safer path.
What Happens When Memantine Is Taken with a Cholinesterase Inhibitor
Many people with moderate-to-severe Alzheimer’s take memantine alongside a cholinesterase inhibitor like donepezil, rivastigmine, or galantamine. When the goal is to simplify the medication list, a common question is whether both drugs can be stopped at once or whether one should go first.
Most deprescribing guidance advises stopping one drug at a time so that any change in the patient’s condition can be attributed to the specific medication that was altered. A 2024 study in JAMA Network Open examined what happens when cholinesterase inhibitors are discontinued at the point memantine is started. The researchers found that dropping the cholinesterase inhibitor when initiating memantine may be reasonable in order to reduce treatment burden, cost, and adverse drug events.8JAMA Network Open. Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults That study addressed the specific scenario of switching from one drug to another, not stopping all dementia medications simultaneously, but it illustrates that thoughtful discontinuation of one agent in the context of combination therapy does not automatically lead to disaster.
If you or a family member are on both drugs and the aim is to stop everything, the standard approach is to taper one medication fully and observe for several weeks before starting to taper the second. Which one to taper first depends on the individual’s symptom profile and the prescriber’s clinical judgment, though some clinicians prefer to stop the cholinesterase inhibitor first because the evidence base for those withdrawal effects is somewhat better characterized than for memantine alone.
Kidney Function and the Pace of Tapering
Memantine is cleared primarily through the kidneys, and impaired kidney function slows that clearance substantially. A pharmacokinetic study found that people with mild or moderate kidney impairment can use the standard dosing regimen without adjustment, but those with severe renal impairment should be on a lower target dose, roughly half of the usual amount.9PubMed. Pharmacokinetic study of memantine in healthy and renally impaired subjects
This matters for tapering because a person with poor kidney function already has a higher drug concentration in their blood relative to their dose. When the drug is reduced, it will take longer to clear from their system. In one sense, that provides a built-in cushion: the effective taper is gentler than the dose change on paper, because the body is lowering its own drug level more slowly. But it also means that side effects from excessive levels could linger after each step-down. If someone has known kidney disease, their prescriber will likely use longer intervals between taper steps and may check kidney function during the process to calibrate the pace.
The Caregiver’s Role in the Decision
For many people on memantine, the decision to stop is not made by the patient alone. Advanced dementia often means the person lacks the capacity to weigh the risks and benefits of continuing or discontinuing a medication. Caregivers, whether family members or professional staff, become the practical decision-makers alongside the prescriber.
Research looking at caregiver experiences with withdrawing dementia medications identified several recurring themes: anxiety about what withdrawal might cause, uncertainty about whether the drug was still helping, and emotional burden during and after the process. Caregivers frequently reported feeling conflicted between wanting to reduce pill burden and fearing that stopping a drug would accelerate decline.10BMC Palliative Care. Caregivers’ perspectives and experiences of withdrawing acetylcholinesterase inhibitors and memantine in advanced dementia: a qualitative analysis of an online discussion forum
One of the most useful things caregivers can do during a taper is keep a simple daily log. Note the person’s mood, sleep, appetite, agitation level, and any changes in what they can do independently. These notes are far more useful to the prescriber than a general sense that “something seems different.” Because the changes that matter can be gradual and easy to rationalize, having a written record creates an objective baseline the care team can refer to when deciding whether to continue the taper, pause, or reverse it.
It also helps to have the conversation about a potential restart before the taper begins. Knowing in advance that going back on the medication is a legitimate and expected option, not a failure, takes some of the emotional weight off both the caregiver and the clinician. The deprescribing guidelines explicitly frame the process as a trial: you try stopping, and if the person is worse off, you restart.
The Evidence Gap Around Memantine Withdrawal
Compared to cholinesterase inhibitors, the research specifically on memantine discontinuation is thin. The Cochrane review that looked at stopping dementia drugs found six trials investigating cholinesterase inhibitor withdrawal and one trial that looked at stopping either donepezil or memantine, but no trials that isolated memantine withdrawal on its own.5PubMed Central. Withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia That means much of the practical guidance for tapering memantine is extrapolated from the drug’s pharmacology, from case reports, and from the broader deprescribing literature rather than from randomized controlled trials designed to answer the question directly.
This gap is not a reason to avoid stopping memantine when stopping is appropriate. It is a reason to approach the process carefully and to lean heavily on monitoring rather than on a fixed protocol. The nursing home study showing worsened cognition and mood after discontinuation provides the strongest available signal that stopping memantine has real consequences, and it underscores why the taper-and-watch model, rather than an abrupt stop, remains the default recommendation.7Journal of the American Medical Directors Association. Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer’s Disease
Off-Label Uses and the Same Tapering Principles
While memantine is approved for moderate-to-severe Alzheimer’s disease, it is sometimes prescribed off-label for other conditions, including chronic pain syndromes, treatment-resistant depression, and certain substance use disorders. The drug’s ability to block overactive NMDA receptor signaling is the pharmacological rationale behind these uses.11PubMed Central. Mechanistic insights into the efficacy of memantine in treating certain drug addictions
If you are taking memantine for an off-label reason, the same general tapering advice applies: step down gradually, monitor for changes, and keep your prescriber in the loop. The specific symptoms to watch for will differ depending on the condition being treated. Someone taking memantine for pain may notice a return of pain at each dose reduction, while someone taking it for mood symptoms may see a shift in emotional stability. The biological rationale for gradual tapering, avoiding a sudden flood of excitatory signaling at the receptor level, does not change just because the diagnosis on the prescription label is different.
One wrinkle with off-label use is that the evidence supporting the original prescription may have been weaker in the first place. If the drug was started as a trial for a condition where the evidence is still preliminary, the threshold for deciding to stop may be lower, and the expectation of benefit from continuing may be less certain. That can actually make the deprescribing conversation easier, because both sides acknowledge upfront that the drug’s value was never guaranteed. The tapering mechanics, however, remain the same regardless of how strong the evidence for starting was.